Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 251, Issue 12, 2013, Pages 2705-2709

  Dalal, Monica ^a   Jacobs El, Naima ^a   Nicholson, Benjamin ^a   Tuo, Jingsheng ^a   Chew, Emily ^a   Chan, Chi Chao ^a   Nussenblatt, Robert ^a   Ferris, Frederick ^a   Meyerle, Catherine ^a  

^a NATIONAL EYE INSTITUTE   (United States)

Author keywords

Akt mTOR; Choroidal neovascularization; Neovascular age related macular degeneration; Palomid 529

Indexed keywords

BEVACIZUMAB; FLUORESCEIN; PALOMID 529; PROTEIN SERINE THREONINE KINASE INHIBITOR; RANIBIZUMAB; STEROID; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

AGED; ARTICLE; AUTOFLUORESCENCE; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYE FUNDUS; EYE PHOTOGRAPHY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; HYPOGLYCEMIA; INDOCYANINE GREEN ANGIOGRAPHY; MACULAR VOLUME; MALE; OPEN STUDY; OPTICAL COHERENCE TOMOGRAPHY; PHASE 1 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT RESPONSE; UREA BLOOD LEVEL; URTICARIA; VERY ELDERLY; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

AGED; AGED, 80 AND OVER; BENZOPYRANS; COLORING AGENTS; CONJUNCTIVA; ENZYME INHIBITORS; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INDOCYANINE GREEN; MALE; MULTIPROTEIN COMPLEXES; PILOT PROJECTS; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84891383442     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-013-2375-7     Document Type: Article

References (18)

1. Coleman HR, Chan CC, Ferris FL III, Chew EY (2008) Age-related macular degeneration. Lancet 372(9652):1835-1845
2. Klein R, Cruickshanks KJ, Nash SD, Krantz EM, Nieto FJ, Huang GH, Pankow JS, Klein BE (2010) The prevalence of age-related macular degeneration and associated risk factors. Arch Ophthalmol 128(6):750-758
3. Nussenblatt RB, Ferris F III (2007) Age-related macular degeneration and the immune response: implications for therapy. Am J Ophthalmol 144(4):618-626
4. Nussenblatt RB, Liu B, Li Z (2009) Age-related macular degeneration: an immunologically driven disease. Curr Opin Investig Drugs 10(5):432-442
5. Patel M, Chan CC (2008) Immunopathological aspects of age-related macular degeneration. Semin Immunopathol 30(2):97-110
6. Liu B, Faia L, Hu M, Nussenblatt RB (2010) Pro-angiogenic effect of IFNgamma is dependent on the PI3K/mTOR/translational pathway in human retinal pigment epithelial cells. Mol Vis 16:184-193
7. Wang Y, Wang VM, Chan CC (2011) The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment. Eye (Lond) 25(2):127-139
8. Tarallo V, Hirano Y, Gelfand BD, Dridi S, Kerur N, Kim Y, Cho WG, Kaneko H, Fowler BJ, Bogdanovich S, Albuquerque RJ, Hauswirth WW, Chiodo VA, Kugel JF, Goodrich JA, Ponicsan SL, Chaudhuri G, Murphy MP, Dunaief JL, Ambati BK, Ogura Y, Yoo JW, Lee DK, Provost P, Hinton DR, Nuñez G, Baffi JZ, Kleinman ME, Ambati J (2012) DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell 149(4):847-859
9. Doyle SL, Campbell M, Ozaki E, Salomon RG, Mori A, Kenna PF, Farrar GJ, Kiang AS, Humphries MM, Layelle EC, O'Neill LA, Hollyfield JG, Humphries P (2012) NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nat Med 18(5):791-798
10. Rosenbaum JT (2012) Eyeing macular degeneration - a few inflammatory remarks. N Engl J Med 367(8):768-770
11. Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, Fruman DA (2010) Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 16(2):205-213
12. Shor B, Gibbons JJ, Abraham RT, Yu K (2009) Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle 8(23):3831-3837
13. Xue Q, Hopkins B, Perruzzi C, Udayakumar D, Sherris D, Benjamin LE (2008) Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Res 68(22):9551-9557
14. Ackah E, Yu J, Zoellner S, Iwakiri Y, Shurk C, Shibata R, Ouchi N, Easton RM, Galasso G, Birnbaum MJ, Walsh K, Sessa WC (2005) Akt1/protein kinase Bα is critical for ischemic and VEGF-mediated angiogenesis. J Clin Invest 115(8):2119-2127
15. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC (1999) Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399(6736):597-601
16. Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ (2002) Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamcyin (mTOR)-dependent signaling. FASEB J 16(8):771-780
17. Dejneka N, Kuroki AM, Fosnot J, Tang W, Tolentino MJ, Bennett J (2004) Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis 10:964-972
18. Paloma Pharmaceuticals, Inc (2009) Palomid 529 investigator's brochure (3rd ed.) [Brochure]